VITROS® SARS-CoV-2 Antigen is a random-access, high-throughput test for the accurate detection of SARS-CoV-2 infection.
High sensitivity provides trust in results.
Available on the high-throughput, fully automated VITROS® XT 7600 and 5600 Integrated Systems, and the VITROS® 3600 Immunodiagnostic System.
Offered with 100% sensitivity (95% CI: 92.0-100%) concordance to <32 CT (PCR Cycle Threshold) - making it a viable alternative to RT-PCR tests.
For the qualitative detection of SARS-CoV-2 nucleocapsid antigen to identify infection.
The performance of the VITROS® SARS-CoV-2 Antigen test is enhanced by the proprietary technologies and benefits only available on VITROS® Systems
May be used with specimens collected from both symptomatic and asymptomatic individuals.
99.2% specificity (95% CI: 95.8%-100%) tested on 131 RT-PCR confirmed negative samples.
Instrument throughput targeted for up to 130 tests per hour on-board instrument.
Maximum flexibility in workflow due to waterless and fully automated VITROS® Systems with random-access testing and continuous sample loading and STAT sample option.
Easy results interpretation with reactive and non-reactive results – no gray zone or repeat testing to significantly impact workflow advantages.
We improve and save lives
We enable our customers to optimize the long-term value for patients through our innovative IVD solutions and services.